Tag: PRELUDE-BTK

Cagent Vascular Announces PRELUDE-BTK Study Results Presented at LINC Symposium: Confirms Serranator Device Novel Mechanism of Action

Peripheral/Endo by 0 comments

WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, a developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its PRELUDE-BTK Study at this year’s LINC Symposium on January 29th. The PRELUDE-BTK Study, was a prospective, single-arm, multi-center feasibility study […]

Continue Reading →

Cagent Vascular Announces FDA 510(k) Clearance for its Serranator Device for the Infrapopliteal Indication and Completion of its PRELUDE-BTK Clinical Trial Enrollment

Peripheral/Endo by 0 comments

WAYNE, Pa.–(BUSINESS WIRE)–Cagent Vascular, a developer of serration technology for vessel dilatation in cardiovascular disease interventions, announces FDA 510(k) Clearance of its Serranator® PTA Serration Balloon Catheter for treating below-the-knee (BTK) lesions. The Serranator device is the first and only angioplasty balloon FDA […]

Continue Reading →